The European Commission’s Pharmaceutical Sector Inquiry raised significant concerns regarding so-called “reverse payment” patent settlement agreements. In this article, CRA describes the types of information or economic evidence that might facilitate evaluation of the competitive aspects of these settlements. To read the article, click here:
Why a hotel room in New York costs $500 a night
In a recent op-ed in The Wall Street Journal titled “Why a Hotel Room in NY Costs $500,” Michael Salinger (CRA consultant and Boston University professor) and...